+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tu1073 Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients With Gastrointestinal Disorders Who Have a History of Unsatisfactory Oral Iron Therapy: Results of a Phase Iii, Randomized, Placebo-Controlled Trial



Tu1073 Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients With Gastrointestinal Disorders Who Have a History of Unsatisfactory Oral Iron Therapy: Results of a Phase Iii, Randomized, Placebo-Controlled Trial



Gastroenterology 144(5): S-754




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067071663

Download citation: RISBibTeXText

DOI: 10.1016/s0016-5085(13)62790-0


Related references

A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology 89(6): 646-650, 2014

Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study. American Journal of Hematology 91(2): E3-E5, 2016

Tu1743 Iv Iron Treatment of Iron Deficiency Anemia with Ferumoxytol in Patients with Inflammatory Bowel Disease Unable to Take Oral Iron: A Randomized Controlled Trial Versus Ferric Carboxymaltose. Gastroenterology 156(6): S-1107-S-1108, 2019

Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clinical and Experimental Gastroenterology 9: 151-162, 2016

Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. Bmc Hematology 16: 20, 2016

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
. Clinical Nephrology 91(4): 237-245, 2019

The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Bmc Nephrology 18(1): 117, 2017

Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Clinical Therapeutics 29(8): 1682-1691, 2007

Treatment of iron-deficiency anemia with IV ferumoxytol in CKD patients: Efficacy compared with oral iron across different age groups. 2007

Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. Journal of the College of Physicians and Surgeons--Pakistan 25(3): 193-197, 2015

Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica 101(1): E6-E7, 2016

Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology 100(11): 2503-2509, 2005

Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine 32(3): 398-403, 2019

Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). Journal of Perinatal Medicine 45(4): 443-453, 2017

Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. Asia-Pacific Journal of Clinical Oncology 14(2): E129-E137, 2018